Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.


Related Content

After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Sage's Oral GABA-A Modulator Shows 'Dramatic' Effect On Depression
PTC To Appeal Translarna's Complete Response Letter From US FDA
Bayer's Aliqopa Approval Gives PI3K Class A Second Chance in Follicular Lymphoma
Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie
Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded
Capricor Eyes RMAT Designation Based On Interim Phase II Data
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts